- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00264394
Cardiovascular Risk Factor Management in HIV Infection
27. mai 2015 oppdatert av: University Hospital, Basel, Switzerland
Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study
There is growing evidence that antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) through metabolic side effects, such as dyslipidemia, insulin resistance, and type II diabetes.
Prevalence of risk factors for CHD in HIV-infected individuals receiving ART in the Swiss HIV Cohort Study (SHCS) is high.
This cluster randomised controlled trial is nested into the SHCS and will investigate whether physicians randomised to the routine provision of risk profiles from their patients receiving ART will improve the management of risk factors in HIV-infected patients compared to control physicians not routinely receiving such information.
Risk profiles will be generated by the SHCS data center and provided to clinicians in all study centers.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
Evidence from the D.A.D. study, an international cohort study which includes a large proportion of SHCS patients, suggests that exposure to antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) most likely due to ART induced metabolic changes like dyslipidemia, insulin resistance, and type II diabetes.
The exact mechanisms for these metabolic changes and whether specific classes or combinations of ART are causally related to these changes are not known.
Of males aged < 40 and > 40 years in the SHCS, 8.8% and 32.5% are at moderate (10% - 20%) and 1.7% and 6.9% at high (≥ 20%) risk of CHD in 10 years according to the Framingham algorithm.
The overall percentage at moderate and high 10-year risk of CHD was 14.9% and 3.0%, respectively.
Therefore, an intervention to reduce CHD risk among individuals at high risk for CHD is warranted.
We propose a randomised controlled cluster intervention trial to reduce total cholesterol in all HIV-infected individuals in the SHCS (primary endpoint) and in those with greater than or equal to 10% 10 year risk of CHD based on the Framingham score (secondary endpoint).
The intervention is the receipt of structured continuously updated information on CHD risk factors and treatment of CHD risk factors of HIV-infected patients.
Randomisation will be done at the physician level and stratified by centre (7 centres of the SHCS, outpatient clinic or hospital), and size of patient volume for registered private practices.
For physicians randomised to the intervention group, a flow sheet with information on risk factors and treatment status of CHD will be provided for each of their patients every 6 months by the SHCS data centre.
Each centre and each physician treating SHCS patients will receive internationally and locally approved guidelines for the management of risk factors for CHD in HIV-infected patients.
The intervention will be limited to 18 months.
Our goal is a 7% reduction in total cholesterol (primary endpoint) between the intervention and the control group in the entire cohort.
With alfa-error of 5%, power of 80% and a loss to follow-up of 10%, 408 patients per arm will be needed.
Sample size calculations adapted to the cluster design of the trial show that we have sufficient power to detect a 12% reduction in total cholesterol in patients receiving ART and at moderate to high risk of CHD.
Further secondary endpoints are a reduction of systolic and diastolic blood pressure and of overall Framingham risk score.
We will additionally monitor whether changes in ART due to high risk of CHD, or treatment of CHD risk factors decreases the proportion of patients with non-sustained control of HIV-viremia.
Data from this nested cluster trial will provide important information as to whether provision of an individual's CHD profile will improve monitoring and reduce CHD risk factors in HIV-infected patients in the SHCS.
Studietype
Intervensjonell
Registrering (Faktiske)
4097
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Berne, Sveits, CH-3010
- Klinik und Poliklinik für Infektiologie, Inselspital
-
Geneva, Sveits, CH-1211
- Division des Maladies Infectieuses, Hopital Universitaire Geneve
-
-
Canton St. Gall
-
St. Gallen, Canton St. Gall, Sveits, CH-9007
- Departement Innere Medizin Kantonsspital St. Gallen
-
-
Canton Ticino
-
Lugano, Canton Ticino, Sveits, CH-6903
- Ospedale civico Lugano
-
-
Canton Zurich
-
Zurich, Canton Zurich, Sveits, CH-8091
- Abteilung für Infektionskrankheiten & Spitalhygiene, Universitätsspital Zürich
-
-
Kanton Basel Stadt
-
Basel, Kanton Basel Stadt, Sveits, CH-4031
- University Hospital Basel
-
-
Vaud
-
Lausanne, Vaud, Sveits, CH-1011
- Division Maladies Infectieuses, Hopital Universitaire Vaudois (CHUV)
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
For analysis of the primary endpoint:
All individuals in the SHCS
- aged 18 or older
- have a cohort visit in the 12 months preceding the randomisation date with a complete baseline dataset on CHD risk factors
For analysis of secondary endpoints:
All individuals in the SHCS
- aged 18 or older
- have a cohort visit in the 12 months preceding the randomisation date with a complete baseline dataset on CHD risk factors
- at least 3 months of ART and at moderate to high risk of CHD (10% 10 years risk of CHD according to the Framingham risk score).
Exclusion Criteria:
- Pregnant females
- Patients in the SHCS not receiving ART
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Updated CHD risk profiles
Provision of regularly updated CHD risk profiles
|
Provision of computer generated CHD risk profiles
Andre navn:
|
|
Aktiv komparator: Guidelines
Physicians received guidelines only
|
provision of guidelines for CHD risk factor management only
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Reduction in total cholesterol in the entire SHCS population
Tidsramme: 18 months
|
18 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The reduction in total cholesterol, systolic and diastolic blood pressure, and Framingham 10-year CHD risk score in individuals with a greater than or equal to 10% 10 year risk of CHD (according to the Framingham risk profile)
Tidsramme: 18 months
|
18 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Heiner C Bucher, MD, Basel Institute for Clinical Epidemiology University Hospital Basel
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juli 2006
Primær fullføring (Faktiske)
1. oktober 2008
Studiet fullført (Faktiske)
1. februar 2010
Datoer for studieregistrering
Først innsendt
9. desember 2005
Først innsendt som oppfylte QC-kriteriene
9. desember 2005
Først lagt ut (Anslag)
12. desember 2005
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
28. mai 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. mai 2015
Sist bekreftet
1. mai 2015
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Glukosemetabolismeforstyrrelser
- Metabolske sykdommer
- RNA-virusinfeksjoner
- Virussykdommer
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- Sykdommer i immunsystemet
- Arteriosklerose
- Arterielle okklusive sykdommer
- Sykdommer i det endokrine systemet
- Sukkersyke
- Lipidmetabolismeforstyrrelser
- Langsomme virussykdommer
- Hjertesykdommer
- HIV-infeksjoner
- Koronararteriesykdom
- Myokardiskemi
- Koronar sykdom
- Diabetes mellitus, type 2
- Infeksjoner
- Dyslipidemier
- Ervervet immunsviktsyndrom
Andre studie-ID-numre
- SNF 3345-062041 SHCS 480
- 480 (Swiss HIV Cohort Study)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .